Login
OneLife Botanicals expands scope as cannabis manufacturer
Holding Redlich has advised OneLife Botanicals on its latest acquisition geared towards the cannabis industry.
Emma Musgrave
Firm: Holding Redlich (OneLife Botanicals); Undisclosed (MediPharm Labs Inc)
To continue reading the rest of this article, please log in.
Create free account to get unlimited news articles and more!
Deal: OneLife Botanicals has acquired MediPharm Labs Australia from MediPharm Labs Inc.
Value: $7.25 million
Area: Pharmaceuticals; cannabinoids
Key players: The legal team advising OneLife Botanicals included Holding Redlich partner Alyn Tai.
Deal significance: MediPharm Labs Inc is a listed Canadian entity with an Australian subsidiary, MediPharm Labs Australia.
According to a statement provided by Holding Redlich, OneLife Botanical’s acquisition of MediPharm Labs Australia means that OneLife Botanicals becomes one of Australia’s leading cannabis manufacturers.
“The deal is significant from Holding Redlich’s perspective as it emphasises our deep expertise both in the health and manufacturing industries,” the firm’s statement said.
Commenting further, Holding Redlich partner Alyn Tai said: “Holding Redlich is pleased to have advised OneLife Botanicals on its acquisition of MediPharm Labs Australia from Canadian-based MediPharm Labs Inc.
“OneLife Botanicals has now cemented its place as a market leader in the emerging cannabis manufacturing space, and we look forward to working with them towards their next phase of growth and success.
“This deal demonstrates Holding Redlich’s expertise in helping healthcare companies take their businesses to the next level, as well as our breadth of M&A capabilities across various industry sectors.”
